ORPHAGEN PHARMACEUTICALS, INC.
Small molecule SF-1 antagonist (OR-449) for adrenocortical carcinoma
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Total capital
- $8.6M
- Federal grants
- $8.6M
- 12 awards · 2015–2025
- Rank in peer group#412 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $15K
- 1 award · Veterans Affairs
- Rank in Biotech#373 of 4373
- Granted patents
- 2
- 7 pending · first 2025
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells$634K
- Federal grantHealth and Human S · Phase II · A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells$1.1M
- Federal grantHealth and Human S · Phase II · Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer$693K
- Federal grantHealth and Human S · Phase II · Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer$2M
- Federal grantHealth and Human S · Phase II · Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer$1.3M
- Federal grantHealth and Human S · Phase II · Translational feasibility of an oral, non-hormonal, male contraceptive pill$719K
- Federal grantHealth and Human S · Phase II · Translational feasibility of an oral, non-hormonal, male contraceptive pill$1.1M
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase I · HLS-Small Molecule Discovery at Novel Target for Fetal Hemoglobin Induction$161K
- Federal grantHealth and Human S · Phase I · HLS-Small Molecule Discovery at Novel Target for Fetal Hemoglobin Induction$325K
- Federal grantHealth and Human S · Phase I · HLS-Small Molecule Discovery at Novel Target for Fetal Hemoglobin Induction$164K
- Federal grantHealth and Human S · Phase I · Orphan Nuclear Receptor as Novel Drug Discovery Target for Cancer Immunotherapy$225K
- Federal grantHealth and Human S · Phase I · Orphan Nuclear Receptor as Novel Drug Discovery Target for Cancer Immunotherapy$225K
- Federal contractVeterans Affairs · 32-CHANNEL Luminometer For Circadia Biology Research$15K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#142 · top 28%
- Linked publications#63 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 2 granted of 9- GrantedPyrazolopyrimidinone CompoundsUSPTOUS 12,617,799
- GrantedRar-alpha Compounds For Inflammatory Disease And Male ContraceptionUSPTOUS 12,492,177
- PendingModulators Of Retinoid-related Orphan Receptor GammaUSPTOApplication 15975030
Show all 9 patent records
- Pyrazolopyrimidinone CompoundsMay 5, 2026 · US 12,617,799Granted
- Rar-alpha Compounds For Inflammatory Disease And Male ContraceptionDec 9, 2025 · US 12,492,177Granted
- Modulators Of Retinoid-related Orphan Receptor GammaSep 13, 2018 · Application 15975030Pending
- Modulators Of Retinoid-related Orphan Receptor GammaSep 21, 2017 · Application 15592692Pending
- Rar-alpha Compounds For Inflammatory Disease And Male ContraceptionApplication PCTUS2020065719Pending
- Rar-alpha Compounds For Inflammatory Disease And Male ContraceptionApplication 62950473Pending
- Pyrazolopyrimidinone CompoundsApplication 63166739Pending
- Therapeutic Compositions Containing Rar-alpha AntagonistsApplication PCTUS2017033172Pending
- Pyrazolopyrimidinone CompoundsApplication PCTUS2022021890Pending
Recent research by its founders
- A Concise and Modular Approach to Generate Novel RORγ Agonists20251 cites
- A potent and selective RORγ inhibitor for the treatment of autoimmune diseases20250 cites
- Discovery and characterization of OR-449, a potent antagonist to steroidogenic factor-1 (SF-1) and clinical candidate for treatment of ACC20250 cites
Related companies, and why
- Harvard Apparatus Regenerative Technology, Inc.Similar federal contract value in Biotech · $22K in contracts
- TriSalus Life Sciences, Inc.Similar federal contract value in Biotech · $22K in contracts
- Circulomics Inc.Similar federal contract value in Biotech · $19K in contracts
- CHEMBIND LLCSimilar federal contract value in Biotech · $15K in contracts
- BioCardia, Inc.Similar federal contract value in Biotech · $15K in contracts
- Guardant HealthSimilar federal contract value in Biotech · $14K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .